Navigation Links
Zoledronic acid does not prevent bone metastases in high-risk PCa patients
Date:3/19/2013

Milan, 19 March 2013 - The initial study results of the Zometa European Study (ZEUS) showed no difference in the incidence of bone metastases between the Zometa group and control arm, said Prof. Manfred Wirth during the closing and fourth plenary session of the 28th Annual EAU Congress which ends today.

"There is no difference in the incidence of bone metastases and there is no difference in survival," said Wirth in his brief presentation on whether Zometa can prevent bone metastases in high risk, metastatic prostate cancer patients. The ZEUS study, supported by the EAU Research Foundation, looked into the efficacy and safety results after a median follow-up of 50 months. Zoledronic acid (Zometa) is a third-generation nitrogen-containing Bisphosphonate, approved in Europe and the US for the treatment of bone metastases in a broad range of tumours.

Zoledronic acid was expected to show its potential in preventing hormone therapy induced bone loss. Patients were randomised between standard treatment plus Zometa 4 mg infusions every three months for a total of 48 months. "There were regional variations in the numbers of patients who developed bone metastases," added Wirth as he noted that locally treated patients developed less bone metastases.


'/>"/>

Contact: Ivanka Moerkerken
i.moerkerken@uroweb.org
31-026-389-0680
European Association of Urology
Source:Eurekalert

Page: 1

Related medicine news :

1. New drug prevents spread of human prostate cancer cells
2. Antibody therapy prevents gastrointestinal damage following radiation exposure in mice
3. To prevent leukemias dreaded return, go for the stem cells
4. Rapid Asthma Treatment in ER May Prevent Admission
5. Report says new evidence could tip the balance in aspirin cancer prevention care
6. Drug May Prevent Pancreatitis After Digestive Procedure
7. Decision guide reduced uncertainty over breast cancer prevention, study finds
8. HIV Prevention Pill Cost-Effective for High-Risk Men: Study
9. Report outlines successes, challenges in cancer prevention efforts
10. Protein prevents DNA damage in the developing brain and might serve as a tumor suppressor
11. Animated characters keep it real in teen violence prevention videos
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/2/2016)... ... December 02, 2016 , ... Halfway through its partnership with ... preventative dental services to more than 15,900 children 5 years old and younger and ... $38 million over a span of five years to Western University of Health Sciences, ...
(Date:12/2/2016)... Dothan, AL (PRWEB) , ... December 02, 2016 ... ... leaders from across the Dothan-Wiregrass Area in Alabama are expected to attend the ... Mike Schmitz, will help provide scholarship funds for area students and operating support ...
(Date:12/2/2016)... York, NY (PRWEB) , ... December 02, 2016 , ... ... an exclusive interview with Mediaplanet, Dr. Murthy explains how he was inspired to practice ... on I learned that medicine is about more than making diagnoses and prescribing medicine,” ...
(Date:12/2/2016)... ... ... Mediaplanet is proud to announce the launch of its ... therapeutic technologies, and revolutionized nutrition that are helping patients and physicians manage their ... the last 3 decades,” says Dr. Valentine Fuster, a world-renowned cardiologist. “This is ...
(Date:12/2/2016)... ... December 02, 2016 , ... Rijuven Corp launches rejiva ( http://www.rejiva.com ), a ... No other wearable health technology on the market can deliver all that rejiva can. ... meaningful insights about their health than the usual heart rate and steps taken”, adds ...
Breaking Medicine News(10 mins):
(Date:12/4/2016)... 2016   Pairnomix, LLC, a genetic research company ... by the White House, today announced that findings from its ... of candidate therapies for a patient with epileptic encephalopathy caused ... presented at the 70 th Annual Meeting of the ... , December 2-6, 2016.  Pairnomix, unique process ...
(Date:12/4/2016)... , Dec. 3, 2016  Results from the Phase ... an anti-P-selectin antibody, reduced the median annual rate of ... placebo (1.63 vs 2.98, p=0.010) in patients with or ... the data are being featured in the official press ... Hematology (ASH) Annual Meeting and presented during the Plenary ...
(Date:12/4/2016)... Dec. 3, 2016  Findings from a Novartis ... CTL019, an investigational chimeric antigen receptor T cell ... young adult patients with B-cell acute lymphoblastic leukemia ... session at the 58th American Society of Hematology ... p.m.). The global Phase II study found that ...
Breaking Medicine Technology: